Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel Police decry online defamation campaign against female officer in Jerusalem - 2Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- 3Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- 4Phenomenal Web-based MBA Stages for Proficient Headway
- 5Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- Passover under fire: Israelis balance fatigue with cautious hope after month of war
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- Investigating the Advantages of a Bank account: A Complete Aide
- 5 Must-Attempt Fascinating Dishes from Around the World
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Seven deaths possibly linked to malfunctioning glucose monitors
